Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:

	Year Ended December 31,
	2022						2021						2020
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	1,341	$	880	$	2,221	$	1,222	$	919	$	2,141	1,000		$	780	$	1,780
Urology	1,257		516		1,773		1,120		463		1,583		918		368		1,286
Neuromodulation	715		202		917		713		196		909		610		151		761
MedSurg	3,312		1,599		4,911		3,055		1,578		4,633		2,528		1,299		3,827
Interventional Cardiology Therapies	744		1,485		2,228		778		1,431		2,209		728		1,247		1,975
Watchman	915		103		1,019		729		100		829		253		71		324
Cardiac Rhythm Management	1,337		763		2,100		1,214		805		2,019		992		712		1,704
Electrophysiology	275		310		585		128		237		365		118		169		287
Cardiology	3,271		2,662		5,932		2,850		2,572		5,422		2,091		2,199		4,290
Peripheral Interventions	1,048		850		1,899		996		824		1,820		888		689		1,577
Cardiovascular	4,319		3,512		7,831		3,846		3,396		7,242		2,979		2,888		5,866
Other1	—		—		(60)		10		4		13		193		27		219
Total Net Sales	$	7,632	$	5,111	$	12,682	$	6,911	$	4,978	$	11,888	$	5,701	$	4,212	$	9,913

(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

	Year Ended December 31,
Geographic Regions	2022		2021		2020
U.S.	$	7,632	$	6,901	$	5,508
Europe, Middle East and Africa	2,526		2,518		2,097
Asia-Pacific	2,116		2,070		1,781
Latin America and Canada	469		386		307
Other1	(60)		13		219
Total Net Sales	$	12,682	$	11,888	$	9,913
Emerging Markets(2)	$	1,715	$	1,429	$	1,138

(2)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.